Analysts Are Bullish on These Healthcare Stocks: Tyme Technologies Inc (TYME), Mirati Therapeutics (MRTX)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tyme Technologies Inc (TYME) and Mirati Therapeutics (MRTX) with bullish sentiments.

Tyme Technologies Inc (TYME)

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Tyme Technologies Inc today and set a price target of $9.50. The company’s shares closed yesterday at $3.13.

Ramakanth observed:

“We maintain our Buy rating of TYME and our 12-month price target of $9.50 per share. We derive our price target based on a net present value analysis of projected SM-88 revenues through FY2030 assuming a 12% discount rate and 2% terminal growth rate. We derive an rNPV of $1.5B for SM-88 and include $17M in net cash to arrive at a 12-month price target of $9.54 per diluted share, which we round to $9.50. (1) clinical; (2) regulatory; (3) commercial; (4) financial; and (5) intellectual property.”

According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of -3.3% and a 34.9% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Collplant Holdings Ltd, Leap Therapeutics Inc, and Correvio Pharma Corp.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tyme Technologies Inc with a $9.25 average price target, a 195.5% upside from current levels. In a report issued on February 12, Canaccord Genuity also reiterated a Buy rating on the stock with a $9 price target.

See today’s analyst top recommended stocks >>

Mirati Therapeutics (MRTX)

In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on Mirati Therapeutics, with a price target of $85. The company’s shares closed yesterday at $72.85, close to its 52-week high of $73.74.

White said:

“We have updated our model to reflect the change in share count and our cash assumptions based on Mirati’s announcement on the closing of its common stock public offering and the full exercise of the underwriters’ option to acquire additional shares. The public offering was comprised of 1,854,838 shares of common stock at $62.00 per share, with aggregate proceeds to Mirati of approximately $115.0M, before underwriting expenses. Additionally, we have broken out the quarters for 2019 in our model. We have additionally broken out candidate MRTX849 from the early stage pipeline, as Mirati recently announced the dosing of the first patient in its Phase 1/2 trial assessing MRTX849 in advanced solid tumor patients with KRAS G12C mutations. We are raising our price target to $85, up from $65, and reiterate our Buy rating.”

According to TipRanks.com, White is a 5-star analyst with an average return of 13.6% and a 45.8% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.

Mirati Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $73.75, implying a 1.2% upside from current levels. In a report released today, Piper Jaffray also initiated coverage with a Buy rating on the stock with a $85 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts